
The Drugs That Actually Fight Alzheimer's Are Here — and Scotland's Patients May Be Next in Line
After decades of nothing, disease-modifying treatments are changing the Alzheimer's landscape. Now the fight is to get them on the NHS.
Somewhere in Scotland this morning, a woman helped her husband find his glasses for the third time before breakfast. She reminded him, gently, that it was Saturday. She made his tea exactly as he likes it — strong, a splash of milk — and for a moment everything felt normal.
For tens of thousands of Scottish families living with early-stage Alzheimer's disease, mornings like these are precious and precarious. The small forgettings that signal something larger. The quiet dread of what comes next.
But for the first time in decades, "what comes next" may not be inevitable decline. Two new drugs — lecanemab (sold as Leqembi) and donanemab (Kisunla) — have done something no Alzheimer's treatment has managed before: they don't just mask symptoms, they attack the disease itself.
Read full story →






